V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

Natera Executive Compensation (FY25)

NTRA · Executive and director compensation, fiscal 2024 to 2025

The paid brief on Natera

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (8-K): June 16, 2026
7 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Natera brief$1,500Get the executive brief
256 figures on this page: 251 cited to the filing that reported them, 5 calculated from figures it prints. See the citations
Chief executive, fiscal 2025
◇
Steven Chapman
Latest say-on-pay support
=
June 11, 2026
Chief executive pay ratio
◇
To the median employee

More on Natera

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2024 to fiscal 2025
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Steven Chapman: $13,032,674 → $14,957,319 (14.8% higher)
Say-on-pay support: 95.9% → 98.0% (2.1 points higher)
CEO pay ratio: 95:1 → 101:1 (6.3% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is Natera's chief executive and what were they paid?
Steven Chapman, Chief Executive Officer, President and Director, received $14,957,319 in total compensation for fiscal 2025. Compared with the $13,032,674 reported for fiscal 2024, Chapman's total was 14.8% higher.
What was Natera's say-on-pay result?
Shareholders supported the say-on-pay proposal with 98.0% of votes cast for or against in favor at the meeting held June 11, 2026 for fiscal 2025.
Which companies are in Natera's peer group?
Companies named in the disclosed peer group include Alnylam Pharmaceuticals, Inc., BeiGene, Bio-Techne Corporation, BioMarin Pharmaceutical Inc. and Exact Sciences Corporation, among others.
What is Natera's chief executive pay ratio?
The disclosed chief executive pay ratio for fiscal 2025 is 101:1, against median employee compensation of $148,726.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Steven Chapman
Chief Executive Officer, President and Director
◇—◇—◇—◇◇
Matthew Rabinowitz
Executive Chairman
◇—◇—◇——◇
John Fesko
President, Chief Business Officer
◇—◇—◇—◇◇
Solomon Moshkevich
President, Clinical Diagnostics
◇—◇—◇—◇◇
Michael Brophy
Chief Financial Officer
◇—◇—◇—◇◇
Fiscal 2025
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Steven Chapman
Chief Executive Officer, President and Director
◇—◇—◇—◇◇
Matthew Rabinowitz
Executive Chairman
◇—◇—◇——◇
Michael Brophy
Chief Financial Officer
◇—◇—◇—◇◇
Solomon Moshkevich
President, Clinical Diagnostics
◇—◇—◇—◇◇
John Fesko
President, Chief Business Officer
◇—◇—◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2025
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
John FeskoRSU◇——◇——◇
John FeskoPSU◇◇◇—◇—◇
Matthew RabinowitzPSU◇◇◇—◇—◇
Matthew RabinowitzRSU◇——◇——◇
Michael BrophyRSU◇——◇——◇
Michael BrophyPSU◇◇◇—◇—◇
Solomon MoshkevichRSU◇——◇——◇
Solomon MoshkevichPSU◇◇◇—◇—◇
Steven ChapmanPSU◇◇◇—◇—◇
Steven ChapmanRSU◇——◇——◇
Fiscal 2024 are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2025 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Steven ChapmanPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Michael BrophyPSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
John FeskoPSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
RSU◇◇——
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
Solomon MoshkevichPSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
RSU◇◇——
Option◇—◇—
Matthew RabinowitzOption◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
PSU◇◇——
RSU◇◇——
RSU◇◇——
PSU◇◇——
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2025
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Roelof Botha
Lead independent director
◇◇———◇◇
Herm Rosenman
◇◇———◇◇
Rowan Chapman
◇◇————◇
Gail Marcus
◇◇————◇
Monica Bertagnolli
◇◇———◇◇
Ruth Williams-Brinkley
◇◇————◇
Roy Baynes
◇◇———◇◇
James Healy
◇—————◇
Jonathan Sheena, Matthew Rabinowitz and Steven Chapman served on the board in fiscal 2025 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
Earlier years are included in the PDF.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Board equity retainer◇
Total board retainer◇
Lead independent director premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2025
  • Alnylam Pharmaceuticals, Inc. ALNY
  • BeiGene symbol not shown
  • Bio-Techne Corporation TECH
  • BioMarin Pharmaceutical Inc. BMRN
  • Exact Sciences Corporation EXAS
  • Exelixis, Inc. EXEL
  • Guardant Health, Inc. GH
  • Illumina, Inc. ILMN
  • Incyte Corp. INCY
  • Insulet Corp. PODD
  • Ionis Pharmaceuticals, Inc. IONS
  • Masimo Corporation MASI
  • Neurocrine Biosciences, Inc. NBIX
  • Qualys, Inc. QLYS
  • Repligen Corporation RGEN
  • Revvity, Inc. RVTY
  • Sarepta Therapeutics, Inc. SRPT
  • United Therapeutics Corporation UTHR

Say-on-pay history

Shareholder support for the compensation program, by year.
YearMeetingSupportVotes forVotes againstAbstentions
2025June 11, 2026=◇◇◇
2024June 12, 2025=◇◇◇
2023June 12, 2024=◇◇◇
2022June 9, 2023=◇◇◇
2021May 25, 2022=◇◇◇

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when Natera files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact Natera disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where Natera sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether Natera's disclosed peer group is defensible, who names Natera back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
256 figures on this page: 251 cited to the filing that reported them, 5 calculated from figures it prints.
251 cited to the filing
5 calculated from the filing

Documents cited

  1. 0001604821-26-000003
    Item 5.07 Submission of Matters to a Vote of Security Holders
  2. 0001104659-26-047770
    2025 Grants of Plan-Based Awards · CEO Pay Ratio · Director Compensation · Outstanding Equity Awards at 2025 Fiscal Year-End · and 1 more section
  3. 0001104659-25-060626
    Item 5.07 Submission of Matters to a Vote of Security Holders
  4. 0001558370-25-005445
    Summary Compensation Table
  5. 0001104659-24-072800
    Item 5.07 Submission of Matters to a Vote of Security Holders
  6. 0001104659-23-071619
    Item 5.07 Submission of Matters to a Vote of Security Holders
  7. 0001104659-22-067171
    Item 5.07 Submission of Matters to a Vote of Security Holders
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “Natera executive compensation, FY2024–FY2025.” https://intel.velarion.ai/comp/NTRA (accessed 2026).
Short form: data: Velarion

The paid brief for Natera

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
7 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about Natera and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers Natera discloses

The companies named in NTRA's own disclosed peer group.

Alnylam Pharmaceuticals, Inc.Bio-Techne CorporationBioMarin Pharmaceutical Inc.Exact Sciences CorporationExelixis, Inc.Guardant Health, Inc.Illumina, Inc.Incyte Corp.Insulet Corp.Ionis Pharmaceuticals, Inc.Masimo CorporationNeurocrine Biosciences, Inc.Qualys, Inc.Repligen CorporationRevvity, Inc.Sarepta Therapeutics, Inc.United Therapeutics Corporation

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy